Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
{{output}}
Oral cabozantinib tablets (Cabometyx®) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated in the development of... ...
